RFK, Jr., says ibogaine holds unprecedented promise for treating depression. Here’s what the science says

Ibogaine is being promoted by RFK Jr. and other Trump administration figures as a highly promising treatment for depression and PTSD, but experts warn that the evidence is still preliminary compared with other psychedelics like psilocybin. Research on ibogaine in the US is limited because it is a Schedule I drug, and safety concerns are central: ibogaine can be toxic to the heart, with reports of sudden cardiac death. The drug comes from the West African Tabernanthe iboga plant and has long been used in Bwiti spiritual tradition in Gabon. Some renewed momentum comes from observational work involving combat veterans treated with ibogaine in Mexico, including magnesium co-dosing to mitigate cardiac risk, which reported improvements in depression and anxiety. However, researchers stress that there are few randomized, double-blind trials, no head-to-head comparisons, and major unknowns remain including long term effectiveness, context effects, and standardized dosing. Scientists are also exploring safer ibogaine-inspired compounds and noribogaine, and the FDA has approved a Phase 3 trial of noribogaine hydrochloride for alcohol use disorder.